EPIRUS Biopharmaceuticals, Inc. (EPRSQ) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
EPRSQ steht fuer EPIRUS Biopharmaceuticals, Inc., ein Healthcare-Unternehmen mit einem Kurs von $0.00 (Marktkapitalisierung 2K). Bewertet mit 46/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 3. März 2026EPIRUS Biopharmaceuticals, Inc. (EPRSQ) Gesundheitswesen & Pipeline-Uebersicht
EPIRUS Biopharmaceuticals aimed to revolutionize treatment for inflammatory diseases and ultra-rare blood disorders through biosimilar development, offering potential cost-effective alternatives, before filing for Chapter 7 liquidation in 2016, ceasing operations and development.
Investmentthese
Investing in EPRSQ is not advisable due to the company's Chapter 7 liquidation filing in 2016. The company's assets are being liquidated, and there is no ongoing business operation. The potential for return on investment is extremely low. The company's pipeline of biosimilar product candidates, including BOW015, BOW050, BOW070, BOW080, and BOW100, are no longer under development. The company's market capitalization is effectively zero, reflecting its defunct status. Investors should be aware of the high risk associated with investing in companies undergoing liquidation.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Lead product candidate BOW015 was a biosimilar version of Remicade (infliximab) targeting inflammatory diseases.
- Pipeline included biosimilars for Humira (adalimumab), Actemra (tocilizumab), Soliris, and SIMPONI.
- Collaborations with Sun Pharmaceutical Industries Ltd., Livzon Mabpharm Inc., and Polpharma S.A.
- Filed for Chapter 7 liquidation on July 25, 2016.
- Market capitalization is $0.00B, reflecting its defunct status.
Wettbewerber & Vergleichsunternehmen
Staerken
- Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs.
Schwaechen
- Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs.
Katalysatoren
- Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs.
Risiken
- Ongoing: Liquidation risk due to Chapter 7 bankruptcy filing.
- Ongoing: No ongoing business operations.
- Ongoing: No potential for future revenue generation.
Wachstumschancen
- Growth opportunity 1: Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs. Therefore, there are no growth opportunities associated with the company.
- Growth opportunity 2: Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs. Therefore, there are no growth opportunities associated with the company.
- Growth opportunity 3: Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs. Therefore, there are no growth opportunities associated with the company.
- Growth opportunity 4: Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs. Therefore, there are no growth opportunities associated with the company.
- Growth opportunity 5: Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs. Therefore, there are no growth opportunities associated with the company.
Chancen
- Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs.
Risiken
- Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs.
Wettbewerbsvorteile
- Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs. Therefore, there are no competitive advantages associated with the company.
Ueber EPRSQ
Founded in 2011 and headquartered in Boston, Massachusetts, EPIRUS Biopharmaceuticals, Inc. was a biopharmaceutical company dedicated to developing, manufacturing, and commercializing biosimilar therapeutics on a global scale. The company's core strategy revolved around creating biosimilar versions of established biologic drugs, offering potentially more affordable treatment options for a range of diseases. Their lead product candidate was BOW015, a biosimilar version of Remicade (infliximab), targeting inflammatory diseases. The pipeline also included BOW050, a biosimilar of Humira (adalimumab); BOW070, a biosimilar of Actemra (tocilizumab); BOW080, a biosimilar of Soliris; and BOW100, a biosimilar of SIMPONI. These biosimilars were intended to treat a variety of conditions, including rheumatoid arthritis, inflammatory bowel disease, and ultra-rare blood disorders. EPIRUS established strategic collaborations and licensing agreements with companies like Sun Pharmaceutical Industries Ltd., Livzon Mabpharm Inc., and Polpharma S.A. to support its development and commercialization efforts. However, on July 25, 2016, EPIRUS Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court, effectively halting its operations and development programs.
Was das Unternehmen tut
- Developed biosimilar therapeutics.
- Aimed to manufacture biosimilar versions of existing biologic drugs.
- Focused on treatments for inflammatory diseases and ultra-rare blood disorders.
- Sought to commercialize biosimilars globally.
- Partnered with other pharmaceutical companies for development and distribution.
- Filed for Chapter 7 liquidation in 2016.
Geschaeftsmodell
- Develop biosimilar versions of branded biologic drugs.
- Out-license or co-develop biosimilars with partners.
- Commercialize biosimilars directly or through partners.
- Generate revenue through product sales and licensing fees.
Branchenkontext
The biotechnology industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. Companies like ALNAQ, ARTH, GNRS, GWHP, and INTP operate in this space. The biosimilar market offers opportunities for companies to develop and commercialize cost-effective alternatives to existing biologic drugs. However, the industry also faces challenges such as patent disputes, regulatory hurdles, and pricing pressures. EPIRUS Biopharmaceuticals aimed to capitalize on the biosimilar market but ultimately failed due to financial constraints, leading to its liquidation.
Wichtige Kunden
- Patients suffering from inflammatory diseases.
- Healthcare providers prescribing biologic drugs.
- Hospitals and clinics using biologic treatments.
- Pharmaceutical companies partnering for distribution.
Finanzdaten
Chart & Info
EPIRUS Biopharmaceuticals, Inc. (EPRSQ) Aktienkurs: $0.00 (-0.00, -99.00%)
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer EPRSQ verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer EPRSQ.
Kursziele
Wall-Street-Kurszielanalyse fuer EPRSQ.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von EPRSQ auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
EPRSQ OTC-Marktinformationen
EPRSQ wird auf der OTC Other-Marktstufe der OTC Markets gehandelt.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
Was Anleger ueber EPIRUS Biopharmaceuticals, Inc. (EPRSQ) wissen wollen
What are the key factors to evaluate for EPRSQ?
EPIRUS Biopharmaceuticals, Inc. (EPRSQ) currently holds an AI score of 46/100, indicating low score. Key strength: Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs.. Primary risk to monitor: Ongoing: Liquidation risk due to Chapter 7 bankruptcy filing.. This is not financial advice.
How frequently does EPRSQ data refresh on this page?
EPRSQ prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven EPRSQ's recent stock price performance?
Recent price movement in EPIRUS Biopharmaceuticals, Inc. (EPRSQ) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider EPRSQ overvalued or undervalued right now?
Determining whether EPIRUS Biopharmaceuticals, Inc. (EPRSQ) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying EPRSQ?
Before investing in EPIRUS Biopharmaceuticals, Inc. (EPRSQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding EPRSQ to a portfolio?
Potential reasons to consider EPIRUS Biopharmaceuticals, Inc. (EPRSQ) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of EPRSQ?
Yes, most major brokerages offer fractional shares of EPIRUS Biopharmaceuticals, Inc. (EPRSQ) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track EPRSQ's earnings and financial reports?
EPIRUS Biopharmaceuticals, Inc. (EPRSQ) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for EPRSQ earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Company filed for Chapter 7 liquidation in 2016. Information is based on historical data prior to liquidation.